Search results
Author(s):
Roxana Mehran
Added:
3 years ago
Dr Roxana Mehran (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the landmark trialXIENCE 90/28.
XIENCE 90/28 evaluated the safety of 3-month and 1 month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting stents.
Questions
1. What is the…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
In this short and engaging episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most impactful hot-line and late-breaking trials from ESC 2022.
Which trials should we look out for?
Trials covered in detail include:
TAILOR-PCI: Tailored Antiplatelet Therapy Following PCI
ASCEND: A Study of…
View more
Author(s):
Susheel Kodali
Added:
2 years ago
In this interview, Dr Susheel Kodali (Columbia University Medical Center, New York, US) discusses the 30-day results of the TRISCEND trial. He details the key findings of the study so far, and the next steps to be taken.Thismulti-centre, prospective, single-arm study evaluates the safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System
Questions:
1.What is the TRISCEND…
View more
Author(s):
Karthiek R Narala
,
Thomas A LaLonde
,
Sohail Hassan
,
et al
Added:
3 years ago
Chronic kidney disease (CKD) affects approximately 26 million people in the US.1 CKD is considered a coronary risk equivalent and also a risk factor for progression of cardiovascular disease (CVD).2 Cardiovascular death rates are 10–30 times higher in dialysis patients than in the general population.3 This increase in CKD patients is multifactorial and is now mainly considered via two pathways:…
View more
Usman Baber
Research Area(s) / Expertise:
Job title: Associate Professor of Medicine
Author
Author(s):
Antonio Gutierrez
,
Sunil V Rao
Added:
3 years ago
Current evidence-based therapies for ischemic heart disease include antithrombotic and antiplatelet medications that reduce the risk for ischemic outcomes such as myocardial infarction and stroke.1 Given their mechanism of action, bleeding is a risk with these agents, especially when combined with invasive procedures.2 In addition to overt bleeding, clinical trials of antithrombotic strategies…
View more
Author(s):
Richard Solomon
Added:
3 years ago
The use of iodinated contrast media (CM) for both diagnostic imaging and interventional studies continues to increase. The introduction of multi-detector computed tomography (MDCT) scanners allows for quicker imaging of internal organs, and image acquisition is now fast enough for study of the coronary arteries. This technology requires the delivery of a high concentration of iodine to the…
View more
Author(s):
Masahiro Natsuaki
Added:
7 months ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111).
In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at…
View more
Author(s):
Ziad A Ali
Added:
7 months ago
ESC 2023 — Dr Ziad Ali (DeMatteis St Francis, US) joins us to discuss the findings from the ILUMIEN IV clinical trial (NCT03507777).
ILUMIEN IV (Abbott Medical Devices)is a prospective, single-blind clinical trial aiming to compare optical coherence tomography (OCT) to an angiography-guided stent implantation strategy. The trial investigated which method achieved a larger post-percutaneous…
View more
Author(s):
Gregory J Dehmer
Added:
3 years ago
In what is often cited as the earliest public reporting of healthcare information, Florence Nightingale published mortality rates at British military hospitals caring for casualties of the Crimean War.1 Dr Ernest Codman, about 50 years later, called for the public release of surgical outcomes at his hospital, but was highly criticized for his effort eventually leading to the loss of his hospital…
View more